美国医药市场迎来突破性进展——万达生物制药旗下新型晕动症治疗药物Nereus™（Tradipitant）正式启动商业销售。这款神经激肽-1受体拮抗剂成为四十多年来首个针对晕动症的创新药理疗法，标志着该领域治疗空白终被填补。
临床研究显示，口服Nereus™能有效阻断引发恶心呕吐的关键神经信号通路。与传统抗组胺药物相比，其独特机制可避免嗜睡等副作用，为长期受晕动症困扰的旅客、船员及虚拟现实设备使用者提供更安全的选择。
值得注意的是，该药物曾于2023年完成三期临床试验，数据显示用药组晕动症状发生率降低超70%。美国FDA基于加速审评通道予以批准，凸显其临床需求的紧迫性。分析师认为，这款年销售额潜力逾3亿美元的产品，或将重塑晕动症治疗市场格局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.